Название продукции:2,4-Dichloropyridine

IUPAC Name:2,4-dichloropyridine

CAS:26452-80-2
Молекулярная формула:C5H3Cl2N
Чистота:98%
Номер в каталоге:CM102599
Молекулярная масса:147.99

Упаковочная единица Доступно для заказа Цена ($) Количество
CM102599-100g in stock ƞŢ
CM102599-500g in stock ưưƞ
CM102599-1000g 1-2 Weeks ŢŔȎ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:26452-80-2
Молекулярная формула:C5H3Cl2N
Точка плавления:-
Smiles-код:ClC1=CC(Cl)=NC=C1
Плотность:
Номер в каталоге:CM102599
Молекулярная масса:147.99
Точка кипения:193.1°C at 760 mmHg
Номер Mdl:MFCD00955618
Хранение:Store at 2-8°C.

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.

Column Infos

Vimseltinib
Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.
Fenebrutinib
Roche’s investigational drug, Fenebrutinib has shown brain penetration and significant reduction in lesions in patients with relapsing multiple sclerosis (MS) from the recent release of new data from Phase II FENopta study. Fenebrutinib is a potent and highly selective Bruton’s tyrosine kinase (BTK) inhibitor, and currently the only reversible inhibitor being tested in Phase III MS trials. BTK inhibitor is involved in key pathological features of MS, including B-cell development and activation.